"10.1371_journal.pone.0147739","plos one","2016-02-10T00:00:00Z","Bettina Schlick; Petra Massoner; Angelika Lueking; Pornpimol Charoentong; Mirjam Blattner; Georg Schaefer; Klaus Marquart; Carmen Theek; Peter Amersdorfer; Dirk Zielinski; Matthias Kirchner; Zlatko Trajanoski; Mark A Rubin; Stefan Müllner; Peter Schulz-Knappe; Helmut Klocker","Division of Experimental Urology, Dept. of Urology, Medical University of Innsbruck, Innsbruck, Austria; ONCOTYROL, Center for Personalized Cancer Medicine, Innsbruck, Austria; Protagen AG, Dortmund, Germany; Department of Pathology, Medical University of Innsbruck, Innsbruck, Austria; Division of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria; Department of Pathology and Laboratory Medicine, Institute of Precision Medicine, Weill Medical College of Cornell University, New York, NY, United States of America; TARGOS Molecular Pathology GmbH, Kassel, Germany","Conceived and designed the experiments: BS PM PA PSK SM HK. Performed the experiments: BS PM AL MB GS DZ MK. Analyzed the data: BS PC CT KM ZT DZ MAR. Contributed reagents/materials/analysis tools: GS SM DZ PSK. Wrote the paper: BS PA HK. Supervision of the project: HK SM PA.","The study was supported by COMET K1 Center Oncotyrol—Center for Personalized Medicine, financed by the Austrian Research Promotion Agency (FFG) and the Future Foundation of the Country of Tyrol, and Protagen AG. Petra Massoner, Georg Schaefer and Bettina Schlilck were employed by ONCOTYROL. Angelika Lueking, Klaus Marquart, Carmen Theek, Peter Amersdorfer, Stefan Müllner and Peter Schulz-Knappe were employed by Protagen AG. Stefan Müllner is the cofounder and CEO of Protagen AG. Dirk Zielinski and Matthias Kirchner were employed by TARGOS Molecular Pathology GmbH. Petra Massoner is currently affiliated as a DAAD fellow with Roche Diagnostics GmbH, however, her data included in the study were generated before that affiliation, study presented herein is independent of the fellowship or any other work related to Roche Diagnostics GmbH. Protagen AG holds a patent on “Marker Sequences for Diagnosing Prostate Cancer, and the Use Thereof”. There are no products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials as detailed online in the guide for authors.","2016","02","Bettina Schlick","BS",16,TRUE,6,7,7,3,TRUE,TRUE,FALSE,0,NA,FALSE
